A 59-Year-Old Man With Relapsed Follicular Lymphoma
A 59-Year-Old Man With Relapsed Follicular Lymphoma
Case: A 59-Year-Old Man With Symptomatic Follicular Lymphoma
A 59-year-old man presented to his physician with a 10-lb weight loss and chronic night sweats for the past couple of months. He complained of intermittent fatigue but is able to maintain his current exercise regimen.
H & P
- PE: enlarged bilateral axillary lymph nodes; enlarged spleen, palpable
- CBC: WBC, 12 X 104/L; platelets,103 X 109/L; Hgb, 9.2 g/dL
- LDH: 400 U/L
Biopsy
- Excisional biopsy showed grade 2 follicular lymphoma; CD20+, CD10+
- Bone marrow biopsy; 60% involved
Imaging
- PET/CT showed widespread lymphadenopathy and a large splenic mass measuring 10 cm
- Diagnosis: Stage IV follicular lymphoma
Teatment
- Started on R-CHOP; tolerated induction well
- Post-therapy PET showed partial remission
- Followed by Rituximab maintenance until evidence of disease progression
Follow-up
- Core needle biopsy; performed confirmed persistent follicular lymphoma; no transformation
- PET at 12 months showed increased size of splenic mass
- ECOG, 0
- Patient started on obinutuzumab + bendamustine
Does Odronextamab Show Hope in FL and DLBCL Despite Regulatory Hurdles?
November 5th 2024Despite regulatory challenges from the FDA, odronextamab has received European approval for the treatment of patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma following 2 prior treatments.
Read More
Phase 3 Trial of Tafasitamab in Follicular Lymphoma Meets Primary End Point
August 16th 2024The phase 3 inMIND trial evaluating tafasitamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma showed promising progression-free survival findings, according to topline results.
Read More
Behind the FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma
March 8th 2024Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
Read More
